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ABSTRACT 53 
 54 
Objectives:  Outpatient parenteral antimicrobial therapy (OPAT) is increasingly used to treat a wide 55 
range of infections. However, there is risk of hospital readmissions. The study aim was to develop a 56 
prediction model for the risk of 30-day unplanned hospitalisation in patients receiving OPAT. 57 
 58 
Methods:  Using a retrospective cohort design, we retrieved data on 1073 patients who received 59 
OPAT over two years (01/2015 - 01/2017) at a large teaching hospital in Sheffield, UK. We developed 60 
a multivariable logistic regression model for 30-day unplanned hospitalisation and assessed its 61 
discrimination and calibration abilities, and internally validated using bootstrap resampling. 62 
 63 
Results:  The 30-day unplanned hospitalisation rate was 11% (123/1073). The main indication for 64 
hospitalisation was worsening or non-response of infection (42%; 52/123). The final regression 65 
model consisted of age (adjusted odds ratio [aOR], 1.18 per decade; 95% confidence interval [CI], 66 
1.04-1.34), Charlson comorbidity score (aOR, 1.11 per unit increase; 95%CI, 1.00-1.23), prior 67 
hospitalisations in past 12 months (aOR, 1.30 per admission; 95%CI, 1.17-1.45), concurrent 68 
intravenous antimicrobial therapy (aOR, 1.89; 95%CI, 1.03-3.47), and endovascular infection (aOR, 69 
3.51; 95%CI, 1.49-8.28). Mode of OPAT treatment was retained in the model as a confounder. The 70 
model had adequate concordance (c-statistic 0.72; 95%CI 0.67-0.77) and calibration (Hosmer-71 
Lemeshow P=0.546; calibration slope 0.99; 95%CI 0.78-1.21) and low degree of optimism (bootstrap 72 
optimism corrected c-statistic, 0.70). 73 
 74 
Conclusions:  We identified a set of six important predictors of unplanned hospitalisation based on 75 
readily available data. The prediction model may help improve OPAT outcomes through better 76 
identification of high-risk patients and provision of tailored care.  77 
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TEXT 78 
 79 
Introduction 80 
Intravenous (IV) antimicrobials are increasingly administered in outpatient settings to treat a wide 81 
range of infections in patients who require parenteral therapy, but are otherwise well enough not to 82 
need hospitalisation. Outpatient parenteral antimicrobial therapy (OPAT) has been shown to be safe, 83 
clinically efficacious and cost-effective with high levels of patient satisfaction and acceptability.
1-8
  84 
Despite its benefits, OPAT is potentially associated with increased clinical risk due to reduced 85 
monitoring and supervision. Even with careful patient selection and multidisciplinary team (MDT) 86 
driven therapeutic plans, the nature of the infections treated and durations of treatment mean 87 
readmission for some patients is inevitable. Thirty-day readmission rates have been used in the UK 88 
and internationally as a marker of health care quality.
9
 Predicting and preventing unplanned 89 
hospitalisation could improve patient outcomes and reduce healthcare costs. Few studies have 90 
assessed risk factors for unplanned hospitalisation in OPAT.
10-12
 To the best of our knowledge, no risk 91 
prediction models for hospitalisation have been developed for patients receiving OPAT within the UK 92 
National Health Service.  93 
 94 
This study aimed to identify factors that might be associated with increased risk of hospital 95 
readmission in an OPAT service based in a large tertiary referral teaching hospital in Sheffield, UK 96 
and to develop a predictive model for 30-day unplanned hospitalisation. The development of an 97 
accurate prediction rule may help identify high-risk patients, and provide personalised care and 98 
support. 99 
 100 
 101 
 102 
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Methods  103 
Patient Population and Setting 104 
We performed a retrospective analysis of all patients who received OPAT between January 2015 and 105 
January 2017 at Sheffield Teaching Hospitals (STH), South Yorkshire, England. The Sheffield OPAT 106 
service, established in January 2006, is one of the largest in the UK. The OPAT service, patient 107 
selection criteria, and a prospectively maintained database have been previously described.
13 
Patient 108 
selection, antimicrobial regimens and mode of OPAT delivery were the responsibility of the OPAT 109 
physicians.   110 
 111 
Data Collection 112 
The OPAT database, hospital electronic clinical and laboratory databases were reviewed. Data 113 
extracted included patient demographics, comorbidities, hospitalisation at STH in the previous 12 114 
months, treatment indication, microbiology culture data, antimicrobial regimen, mode of OPAT 115 
delivery, type of IV access, length of OPAT stay, OPAT outcome, prior OPAT stay, hospital 116 
readmission, reason and length of hospitalisation. Age (years) was determined at the time of 117 
commencing OPAT.  Weighted Charlson comorbidity score was calculated for each patient and was 118 
determined at the time OPAT commenced.
14
 Drug-resistant organisms were defined as methicillin-119 
resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, multi-drug-resistant 120 
tuberculosis, extended-spectrum beta-lactamases producing bacteria and multidrug-resistant 121 
Candida. 122 
 123 
The primary outcome was 30-day unplanned hospitalisation, defined as unplanned inpatient 124 
admission to an acute care hospital for any reason within 30 days of discharge from the OPAT 125 
service. 126 
 127 
 128 
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Sample Size 129 
To ensure a reliable prediction model, we adhered to the accepted rule of having at least 10 events 130 
per regression coefficient estimated.
15
 We planned for 15 predictor degrees of freedom. Using an 131 
anticipated hospitalisation rate of 10% with approximately 750 OPAT episodes per year, we chose to 132 
review two years’ worth of OPAT records to ensure adequate sample size for formulating the model. 133 
 134 
Statistical Analysis 135 
Because some patients had more than one episode of OPAT treatment during the study period, we 136 
performed individual level analysis by taking a simple random sample of one OPAT episode per 137 
patient.  Univariate analysis was performed to describe differences between patients with 30-day 138 
unplanned hospitalisation and those without, and to confirm expected predictive relations from 139 
previous studies. Crude associations were quantified using odds ratios (OR) with 95% confidence 140 
intervals (95%CI) calculated by binary logistic regression.  141 
 142 
A multivariable logistic regression model was developed to predict the risk of unplanned 143 
hospitalisation within 30 days of discharge from OPAT.  We initially considered 13 predictor variables 144 
based on review of the literature, clinical relevance and data availability at time of OPAT initiation. 145 
These included patient sex, age, number of prior hospitalisations in the past 12 months, Charlson 146 
comorbidity score, mode of antimicrobial delivery, drug-resistant organisms, concurrent intravenous 147 
antimicrobial therapy, four antimicrobial classes (penicillin, cephalosporin, carbapenem and 148 
glycopeptide), indication for OPAT and type of vascular access (peripheral vs. central).
10-12,16-23
  None 149 
of the candidate predictor variables had missing values in our database. To minimize the risk of 150 
overfitting, no exploratory search beyond the pre-specified set of predictors was carried out. 151 
 152 
To limit collinearity and ensure a parsimonious prognostic model, we examined Spearman’s 153 
correlations and variance inflation factors among the 13 initial predictors. Of the four antimicrobial 154 
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classes examined, we retained only the cephalosporin in the analysis because it had strong negative 155 
correlations with other classes and is the most commonly prescribed antimicrobial class in OPAT 
1,5,12
 156 
(limiting candidate predictors to 10 variables). We assessed nonlinear effects of continuous variables 157 
using restricted cubic splines. A linear relationship with the log odds of 30-day unplanned 158 
hospitalisation was found to be a good approximation for age, Charlson score and the number of 159 
prior hospitalisations.  160 
 161 
Following the fit of the logistic regression model with the pre-selected set of 10 predictors, those 162 
that did not retain statistical significance (at the alpha level of 0.05) were tested for confounding and 163 
predictive contributions by dropping them one at a time starting from the least significant. 164 
Predictors that caused substantial confounding (change in model coefficient by at least 10%) or 165 
improved prediction (non-zero difference in c-statistic of nested models) were retained in the 166 
model. We also considered changes in the Bayesian Information Criterion (BIC) during this process. 167 
To provide a graphical depiction of all variables in the final risk-prediction model and enable an 168 
approximate computation of output probabilities, we constructed a Kattan-style nomogram in which 169 
the length of the line corresponding to a given predictor is indicative of its importance. Points were 170 
assigned to each predictor variable and total points corresponded to an absolute predicted risk for 171 
30-day unplanned hospitalisation. 172 
 173 
The validity of the final model was assessed by estimating its concordance and calibration ability. 174 
Model calibration (agreement between observed outcomes and predictions) was assessed by the 175 
Hosmer–Lemeshow goodness-of-fit test and by evaluating how much the slope of the calibration 176 
line (plotting the predicted probabilities against the observed probabilities) deviates from the ideal 177 
of 1.0. Discrimination ability (the extent to which the model distinguishes patients with unplanned 178 
hospitalisation from those without) was assessed using the concordance statistic (c-statistic). 179 
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Internal validation was carried out by calculating the c-statistic with correction for ‘optimism’ 180 
overfitting using 200 bootstrap samples.  181 
 182 
Data were processed and analysed using STATA/IC v.13.1 (StataCorp, College Station, TX). The 183 
nomolog program was used to produce the nomogram.
24
 184 
 185 
Ethical approval for this study was not deemed necessary as the data were routinely collected and 186 
analysed for clinical governance, service development and service evaluation activities. The study 187 
complies with the transparent reporting of studies developing multivariable prediction models for 188 
individual prognosis (TRIPOD) statement.
25
 189 
 190 
 191 
Results 192 
Cohort characteristics 193 
Over the two-year study period, we recorded 1324 episodes of OPAT in 1073 individual patients. To 194 
develop the risk prediction model, a random sample of one episode per patient was selected. Table 195 
1 shows the demographic and clinical characteristics of the cohort. The mean age of the patients was 196 
56 (range 16-95) years and 57% (611/1073) were male. Skin and soft tissue infection (SSTI) was the 197 
most common indication for OPAT (616/1073; 57%) and use of cephalosporins (577/790; 73%). Most 198 
patients received intravenous therapy by attending the infusion centre daily (767/1073; 71%). The 199 
median duration of OPAT was seven days (IQR 4-19; range <1 to 261). 200 
 201 
Hospitalisation within 30 days of discharge from the OPAT service was recorded in 14% (145/1073) 202 
patients. The majority of these hospitalisations were unplanned (123/1073; 11%; 95%CI 9.6% - 203 
13.4%). 78 of the 123 patients (63%) with unplanned hospitalisation were admitted during OPAT 204 
treatment. Half of these patients (38/78; 49%) were admitted within the first week of treatment. 205 
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More than a third of the patients (17/45; 38%) that required hospitalisation after completion of 206 
OPAT were admitted two weeks after OPAT therapy. Reasons for the unplanned hospitalisation are 207 
shown in Table 2. The leading indication for hospitalisation was progression or non-response of 208 
infection (52/123; 42%). The median length of hospitalisation was five days (IQR 2-10; range <1 to 209 
114 days).  210 
 211 
Univariate (unadjusted) analysis 212 
Patients with unplanned hospitalisation were older (mean 61 vs. 56 years), had higher Charlson 213 
comorbidity score (median 2 vs. 1) and more prior hospital admissions in the past 12 months 214 
(median 1 vs. 0) compared to patients without 30-day unplanned hospitalisation (Table 1). 215 
Unplanned hospitalisation was also more likely to have occurred in patients who had received OPAT 216 
by a community nurse as opposed to an infusion centre, patients with central vascular access 217 
devices as opposed to peripheral access, and patients treated for endovascular, urogenital or bone 218 
and joint infections as opposed to SSTI. Regarding antimicrobial class, unplanned hospitalisation was 219 
positively associated with receipt of penicillin, carbapenem and glycopeptide, but negatively 220 
associated with use of cephalosporin. Patients who had an unplanned hospitalisation were also 221 
more likely to have been treated simultaneously with multiple parenteral antimicrobial agents.  222 
  223 
Multivariable Model 224 
Results of logistic regression analysis are shown in Table 3 for the full set of the 10 pre-selected 225 
predictors (model 1) and for the model that retained only predictors with important predictive 226 
contribution or confounding effects (model 2). Age, prior non-OPAT hospitalisation in the past 12 227 
months, endovascular infection and receipt of concurrent intravenous antimicrobial therapy were 228 
independently and significantly associated with increased risk of 30-day unplanned hospitalisation. 229 
Receipt of intravenous cephalosporin therapy was significantly associated with decreased risk of 30-230 
day unplanned hospitalisation. Charlson comorbidity score and mode of OPAT delivery had high p-231 
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values. However, both variables were retained in the model because the former made an important 232 
predictive contribution and the latter was an important confounder. By contrast, patient sex, type of 233 
vascular access device or multidrug resistant organism had no predictive contribution in the risk of 234 
hospitalisation. Because antimicrobial treatment may reflect local practices that may limit 235 
generalisability of the prediction model to different OPAT settings, we examined the possibility of 236 
removing cephalosporin variable from the model. Model discrimination and calibration were 237 
affected only slightly, but the BIC improved slightly supporting the removal of cephalosporin from 238 
the final model (Table 3). 239 
 240 
Independent predictors of the risk of 30-day unplanned hospitalisation in the final model (model 3) 241 
were age (adjusted odds ratio [aOR], 1.18 per decade; 95% confidence interval [CI], 1.04 - 1.34), 242 
Charlson comorbidity score (aOR, 1.11 per unit increase; 95%CI, 1.00 - 1231), prior non-OPAT 243 
hospitalisation in the past 12 months (aOR, 1.30 per prior admission; 95%CI, 1.17 - 1.45), receipt of 244 
concurrent intravenous antimicrobial therapy (aOR, 1.89; 95%CI, 1.03 - 3.47), and treatment for 245 
endovascular infection (aOR, 3.51; 95% CI, 1.49 – 8.28), urogenital infection (aOR, 2.62; 95%CI, 1.27 246 
– 5.43) and bone and joint infection (aOR, 2.09; 95% CI, 1.06 – 4.12) as opposed to SSTI. Mode of 247 
OPAT delivery was retained in the final model as an important confounder. Figure 1 provides a 248 
nomogram of the model’s predicted risks for 30-day unplanned hospitalisation.  249 
  250 
The final model’s discrimination ability was adequate (c-statistic 0.72; 95%CI 0.67 – 0.77) and 251 
internal validation indicated a low degree of overfitting (bootstrap optimism corrected c-statistic, 252 
0.70). Model predicted probabilities ranged between 1.8% and 83.4%. The Hosmer-Lemeshow test 253 
(P=0.546) and the calibration slope (0.99; 95%CI 0.78 – 1.21) indicated a good agreement between 254 
predicted and observed probabilities. In addition, the calibration plot did not indicate a pattern of 255 
either over- or underestimation (Figure 2). 256 
 257 
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Discussion  258 
Our study highlights the fact that patients treated with OPAT are at risk of unplanned hospital 259 
readmission. The rate of unplanned hospitalisation (11%; 123/1073) in our cohort is comparable to 260 
other OPAT studies.
18,21
 Worsening or non-response of infection was the main indication for 261 
unplanned hospitalisation. These patients were readmitted for further management including 262 
change in antimicrobial therapy and source control. We found these factors, which are readily 263 
available at time of commencing OPAT, to be important predictors of unplanned hospitalisation: age, 264 
prior non-OPAT hospitalisations in past 12 months, Charlson comorbidity index score, concurrent 265 
receipt of more than one intravenous antimicrobial agent and indication for OPAT.  266 
 267 
Patient age, underlying comorbid conditions and prior hospital admissions have been recognised as 268 
important patient-related risk factors for hospital readmission in OPAT patients in previous 269 
research.
12,16-18,20,23
 We estimated a relative increase in the odds of 30-day hospitalisation of about 270 
18% per decade increase in age and of about 30% per prior admission of patients attending our 271 
OPAT service, which are close to those reported in a comparable study in Tufts Medical Center in 272 
Boston.
12
 Patients with prior hospital admissions were more likely to be hospitalised because they 273 
usually have more medical comorbidities and were likely to be readmitted due to other conditions. 274 
Using the composite Charlson comorbidity index, we additionally identified an important risk 275 
increase associated with patient multimorbidity (an increase in the odds of 30-day hospitalisation by 276 
11% per unit increase in Charlson score). 277 
 278 
The increased risk of hospitalisation in patients who were treated simultaneously with multiple 279 
parenteral antimicrobial agents (i.e. concurrent antimicrobial therapy) in our cohort may reflect a 280 
higher severity of infection, adverse drug reactions or drug interactions. Similar to other OPAT 281 
services,
1,5,7,10,12,17,19,23
 cephalosporins were the most frequently prescribed parenteral antimicrobial 282 
agent in our cohort (70%; 790/1136). Patients who received IV cephalosporin were less likely to be 283 
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hospitalised. We mostly use IV ceftriaxone to treat patients with uncomplicated SSTI. These patients 284 
are generally well and are at lower risk of hospitalisation. In Glasgow, UK, ceftriaxone therapy was 285 
found to be associated with reduced duration of OPAT in patients with SSTIs.
10
 Nevertheless, we 286 
decided to exclude cephalosporin treatment from our risk prediction model because it might reflect 287 
our specific OPAT setting and might be a less influential clinical factor in other settings. Future 288 
studies should consider examining a potential association between cephalosporin use in OPAT and 289 
readmission.   290 
 291 
Similar to Kouma et al,
20
 we also found a strong association of endovascular infection with 292 
unplanned hospitalisation. Endocarditis accounted for more than two thirds of endovascular 293 
infections treated in our cohort. These patients were properly selected for OPAT in line with national 294 
guidelines. Larraza et al additionally reported respiratory and post intra-abdominal surgery 295 
infections as risk factors for readmission in their cohort.
18
 However, the indication for OPAT 296 
(infection treated) was not identified as a risk factor for readmission in other comparable 297 
studies.
12,16,17,19
  298 
 299 
Unlike other OPAT studies,
12,16,17,19
 we did not identify aminoglycoside use, presence of drug-300 
resistant organisms and length of treatment as predictors of unplanned hospitalisation. In our 301 
cohort, aminoglycosides were administered only in eight patients. We seldom use aminoglycosides 302 
in our OPAT service due to the toxicity of these agents and challenges in therapeutic drug 303 
monitoring in an outpatient setting. Although OPAT administered at home by community nurses 304 
appeared to be associated with an increased risk of hospitalisation in univariate analysis, the 305 
association diminished after adjusting for other predictors. Nevertheless, we retained mode of OPAT 306 
treatment in our risk prediction model as an important confounder. 307 
 308 
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Some limitations of this study should be acknowledged. This was a single-centre study. Although our 309 
epidemiological data are consistent with those reported in different settings in the UK and the 310 
USA,
10-12,16,17
 our risk prediction model needs to be externally validated to assess its generalisability 311 
to patients treated in other settings. Our analysis was retrospective, but the data were originally 312 
collected prospectively, which reduces the risk of measurement bias or poor accuracy of data 313 
records. However, we cannot be certain that we have not missed some patients who were 314 
readmitted to other hospitals. The potential for undocumented hospital readmissions might result in 315 
an underestimate of the actual risk of 30-day hospitalisation. Nevertheless, most patients’ 316 
interactions with healthcare systems are documented in their clinical records, and they were usually 317 
reviewed four to six weeks after completion of OPAT. Despite extensively analysing factors 318 
previously reported to be associated with hospitalisation, we cannot be certain that we have not 319 
missed other important predictors or that unrecorded confounders may have influenced our 320 
findings. We did not explore factors (such as therapeutic drug levels, frequency of monitoring or 321 
follow-up visits) that are not readily available pre-OPAT but are plausible readmission risk factors; 322 
our aim was to develop a risk prediction model based on data available on presentation to the OPAT 323 
service. Our risk prediction model produces excellent agreement (calibration) between observed and 324 
predicted probabilities of 30-day hospitalisation, and the bootstrap internal validation suggests only 325 
a small degree of bias from overfitting the model to our data. However, our model should be 326 
prospectively validated in an independent diverse patient population before use in actual patient 327 
care. We intend to continue the project and are currently planning for quasi-external validation of 328 
the model in future patients in our centre and external validation in patients from other UK centres. 329 
 330 
This study adds to existing literature by showing that patients receiving OPAT are at risk of 331 
unplanned hospitalisations, some of which may be preventable. Averting unnecessary 332 
hospitalisation depends on understanding which patients are likely to be readmitted.  The predictive 333 
model for 30-day unplanned hospitalisation developed in this study is based on six easily obtainable 334 
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variables and has adequate prediction metrics. This model has the potential to identify high-risk 335 
patients upon presentation to the OPAT service at a large tertiary referral teaching hospital, thereby 336 
informing evidence-based interventions, and personalised care and support to prevent hospital 337 
readmissions. Further research is required to assess how this model may perform in different 338 
settings, and to elucidate how it may be incorporated into clinical practice to improve the care of 339 
patients receiving OPAT.  340 
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FIGURE CAPTIONS 1 
 2 
Figure 1. Prediction rule nomogram for the risk of 30-day unplanned hospitalisation following 3 
outpatient parenteral antimicrobial therapy.  4 
 5 
Abbreviations: BJI, bone and joint infection; CN, community nurse; EI, endovascular infection; IC, 6 
infusion centre; IV, intravenous; OT, other indication; RD, respiratory disease; SC, self/carer 7 
administration; SSTI, skin and soft tissue infection; UGI, urogenital infection. 8 
 9 
 10 
 11 
Figure 2. Calibration plot for the final model of the risk of 30-day unplanned hospitalization in 12 
patients receiving outpatient parenteral antimicrobial therapy. 13 
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TABLES 1 
 2 
Table 1. Demographic and Clinical Characteristics of Patients Receiving Outpatient Parenteral Antimicrobial Therapy 3 
 4 
Characteristic 
With 30-day 
unplanned 
hospitalisation 
(n = 123) 
Without 30-day 
unplanned 
hospitalisation 
(n = 950) Odds ratio (95%CI)
 1
 
Male sex 67 (54.5) 544 (57.3) 0.89 (0.61 - 1.30) 
Age in years, mean (SD) 60.8 (17.1) 55.5 (17.5) 1.02 (1.01 - 1.03) 
Comorbidities, n (%)    
Chronic pulmonary disease 34 (27.6) 163 (17.2) 1.84 (1.20 - 2.83) 
Diabetes with complications 21 (17.1) 88 (9.3) 1.42 (1.10 - 1.84) 
Peripheral vascular disease 19 (15.4) 68 (7.2) 2.37 (1.37 - 4.10) 
Diabetes without complications 9 (7.3) 98 (10.3) 0.69 (0.34 - 1.40) 
Tumour without metastasis 16 (13.0) 74 (7.8) 1.33 (1.00 - 1.77) 
Moderate or severe renal disease 20 (16.3) 62 (6.5) 1.67 (1.27 - 2.19) 
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Connective tissue disease 12 (9.8) 59 (6.2) 1.63 (0.85 - 3.13) 
Myocardial infarction 19 (15.4) 60 (6.3) 2.71 (1.56 - 4.72) 
Cerebrovascular disease 7 (5.7) 42 (4.4) 1.30 (0.57 - 2.97) 
Congestive heart failure 12 (9.8) 41 (4.3) 2.40 (1.22 - 4.70) 
Peptic ulcer disease 7 (5.7) 33 (3.5) 1.68 (0.72 - 3.88) 
Moderate or severe liver disease 8 (6.5) 17 (1.8) 1.56 (1.17 - 2.08) 
Metastatic solid tumour 1 (0.8) 20 (2.1) 0.85 (0.61 - 1.19) 
Lymphoma 1 (0.8) 7 (0.7) 1.05 (0.37 - 3.01) 
Leukaemia 1 (0.8) 10 (1.1) 0.88 (0.31 - 2.46) 
Hemiplegia 0 (0.0) 6 (0.6) - 
Dementia 1 (0.8) 5 (0.5) 1.55 (0.18 - 13.37) 
AIDS 0 (0.0) 2 (0.2) - 
Mild liver disease 0 (0.0) 0 (0.0) - 
Charlson comorbidity score, median (IQR) 2 (0 - 3) 1 (0 - 2) 1.23 (1.13 - 1.34) 
Indication for OPAT, n (%)    
Skin and soft tissue infection 48 (39.0) 568 (59.8) 1.00 (Ref.) 
Bone and joint infection 22 (17.9) 115 (12.1) 2.26 (1.31 - 3.90) 
Urogenital infection 13 (10.6) 57 (6.0) 2.70 (1.38 - 5.28) 
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Respiratory disease 6 (4.9) 39 (4.1) 1.82 (0.73 - 4.52) 
Endovascular infection 11 (8.9) 34 (3.6) 3.83 (1.82 - 8.03) 
Other indication 23 (18.7) 137 (14.4) 1.99 (1.17 - 3.38) 
Multidrug resistant organism, n (%) 15 (12.2) 71 (7.5) 1.72 (0.95 - 3.11) 
Mode of antimicrobial delivery, n (%)    
Infusion centre 75 (61.0) 692 (72.8) 1.00 (Ref.) 
Self/carer administration 15 (12.2) 90 (9.5) 1.54 (0.85 – 2.79) 
Community nurse 33 (26.8) 168 (17.7) 1.81 (1.16 – 2.82) 
Type of Vascular Access, n (%)    
Central line 54 (43.9) 261 (27.5) 2.07 (1.41 - 3.03) 
Peripheral access 69 (56.0) 689 (72.5) 1.00 (Ref.) 
Antimicrobial agent, n (%)
2,3
    
Penicillin 19 (15.4) 74 (7.8) 2.16 (1.26 - 3.72) 
Cephalosporin 66 (53.7) 724 (76.2) 0.36 (0.25 - 0.53) 
Carbapenem 22 (17.9) 82 (8.6) 2.31 (1.38 - 3.85) 
Glycopeptide 21 (17.1) 77 (8.1) 2.33 (1.38 - 3.94) 
Other 8 (6.5) 43 (4.5) 1.47 (0.67 - 3.20) 
Concurrent intravenous antimicrobial therapy, n (%) 21 (17.1) 60 (6.3) 3.05 (1.78 - 5.23) 
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Oral antibiotic included, n (%) 8 (6.5) 114 (12.0) 0.51 (0.24 - 1.07) 
Duration of OPAT in days, median (IQR) 9 (4 - 20) 7 (4 - 19) 1.00 (0.98 - 1.01) 
Number of prior hospitalisations, median (IQR)
4
 1 (0 - 3) 0 (0 - 1) 1.38 (1.26 - 1.52) 
Prior OPAT stay in past 12 months, n (%) 23 (18.7) 150 (15.8) 1.23 (0.75 – 1.99) 
Initiation of OPAT as inpatient, n (%) 87 (70.7) 615 (64.7) 1.32 (0.87 - 1.98) 
 5 
AIDS,  acquired immunodeficiency syndrome; CI, confidence interval; OPAT, outpatient parenteral antimicrobial therapy; SD, standard deviation; IQR, interquartile range.   6 
1 
Odds ratios for numerical variables refer to unit increases. 7 
2 
The reference category for each antimicrobial agent is receipt of any other antibiotic (e.g. receipt of penicillin vs no penicillin).  8 
3 
Some patients received more than one parenteral antimicrobial agent. Thus, the total number of antimicrobial agents is greater than the total number of patients. 9 
4 
In the 12 months preceding the current OPAT episode.10 
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Table 2. Reasons for 30-Day Unplanned Hospitalisation (n = 123) 11 
Reason for hospitalisation n (%) of patient episodes 
Worsening of existing infection/no improvement 52 (42.3) 
Non-OPAT related  50 (40.7) 
New infection 8 (6.5) 
Adverse drug reaction 7 (5.7) 
Intravenous line-related complications 3 (2.4) 
Clostridium difficile-associated diarrhoea 2 (1.6) 
Unknown 1 (0.8) 
 12 
      OPAT, outpatient parenteral antimicrobial therapy. 13 
 14 
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Table 3. Multivariable Logistic Regression Models for the Risk of 30-Day Unplanned Hospitalisation in Patients Receiving Outpatient Parenteral 15 
Antimicrobial Therapy (n = 1073)  16 
Predictors 
Model 1
1
 Model 2
2
 Model 3 (final)
3
 
aOR 95% CI P value aOR 95% CI P value aOR 95% CI P value 
Male sex 0.77 0.51 – 1.17 0.217 - - - - - - 
Age, per 10 years 1.19 1.04 – 1.35 0.010 1.18 1.03 - 1.34 0.012 1.18 1.04 - 1.34 0.012 
Prior hospitalisations 1.29 1.16 - 1.44 <0.001 1.28 1.15 - 1.43 <0.001 1.30 1.17 - 1.45 <0.001 
Charlson comorbidity score 1.10 0.99 – 1.22 0.065 1.09 0.99 - 1.21 0.082 1.11 1.00 – 1.23 0.045 
Mode of delivery        
Infusion center 1.00 - - 1.00 - - 1.00 - - 
Self/carer administration 0.76 0.36 - 1.62 0.484 0.75 0.37 - 1.53 0.426 0.79 0.39 – 1.62 0.525 
Community nurse 0.60 0.33 - 1.10 0.098 0.60 0.33 - 1.07 0.083 0.62 0.35 – 1.11 0.108 
Multidrug resistant organism 0.71 0.35 – 1.44 0.342 - - - - - - 
Concurrent IV  antimicrobial therapy 2.15 1.15 – 4.01 0.017 2.01 1.09 - 3.70 0.026 1.89 1.03 – 3.47 0.041 
Receipt of intravenous cephalosporin 0.49 0.28 – 0.84 0.010 0.55 0.33 - 0.91 0.020 - - - 
Indication for OPAT        
Skin and soft tissue infection 1.00 - - 1.00 - - 1.00 - - 
Bone and joint infection 1.65 0.75 – 3.62 0.212 1.46 0.69 - 3.07 0.318 2.09 1.06 – 4.12 0.032 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
7 
 
 
Urogenital infection 1.84 0.79 – 4.30 0.160 1.74 0.77 - 3.91 0.180 2.62 1.27 – 5.43 0.009 
Respiratory disease 1.28 0.46 – 3.56 0.642 1.22 0.45 - 3.35 0.695 1.55 0.58 – 4.14 0.382 
Endovascular infection 3.19 1.22 – 8.31 0.018 2.74 1.13 - 6.65 0.026 3.51 1.49 – 8.28 0.004 
Other indication 1.96 0.97 – 3.95 0.061 1.78 0.93 - 3.42 0.084 2.17 1.16 – 4.06 0.015 
Central line access 0.85 0.45 – 1.61 0.610 - - - - - - 
 Model performance statistics 
Calibration slope 1.01 0.77 – 1.25 - 0.96 0.68 - 1.25 - 0.99 0.78 – 1.21 - 
HL goodness of fit, x
2
 (df) 7.83 (8) - 0.450 11.79 (8) -  0.161 6.91 (8) -  0.546 
C-statistic 0.74 0.69 - 0.79 - 0.73 0.69 - 0.78 - 0.72 0.67 – 0.77 -  
C-statistic, BOC 0.70 - - 0.71 - - 0.70 - - 
BIC 793.1 - - 774.9 - - 773.3 - - 
 17 
aOR, adjusted odds ratio; BOC, bootstrap optimism corrected; BIC, Bayesian information criterion; CI, confidence interval; df, degrees of freedom; HL, Hosmer-Lemeshow; 18 
IV, intravenous; OPAT, outpatient parenteral antimicrobial therapy. 19 
1 
The initial model (model 1) contains the full set of candidate predictors. 20 
2 
Model 2 retains only predictors with substantial predictive contribution and/or important confounders. 21 
3 
The final model (model 3) excludes the cephalosporin variable (based on the lowest BIC). 22 
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